For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA). Further details regarding the timings of this MTA will be available in due course.
 
Status Suspended
Decision Selected
Process TAG
ID number 882

Timeline

Key events during the development of the guidance:

Date Update
17 June 2016 Suspended. For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA). Further details regarding the timings of this MTA will be available in due course.
17 June 2016 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual